Oncology and Hematology
Oncology and Hematology Clinical Practice
Stay current with Oncology and Hematology education that fits how you practice. ReachMD offers practical, on-demand clinical content for oncologists, hematologists, oncology nurses, pharmacists, fellows, APPs, and the full cancer care team. Explore expert discussions, case-based programs, CME/CE opportunities, industry features, and news across solid tumors, hematologic malignancies, biomarker-driven care, immunotherapy, targeted therapy, supportive care, and more.
Use this page to find relevant oncology and hematology content fast. Browse Project Oncology episodes, jump into CME/CE activities, review expert perspectives, or explore timely updates on evolving treatment strategies and standards of care. New content is added regularly, so you can stay current with emerging evidence, guideline updates, and multidisciplinary approaches to cancer care on your schedule.
Start with the latest programs below or browse by content type to find the Oncology and Hematology education most relevant to your practice.
271-285 of 355
Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
MinuteCE®Clinical Evidence Behind Emerging Targeted Therapy Strategies Across Gynecologic Malignances
Nicoletta Colombo, MD
Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
MinuteCE®Guideline recommendations for first-line treatment intensification with PARP inhibitor combinations in patients with metastatic castration-resistant prostate cancer
Wenxin Xu, MD
Sandy Srinivas, MD
Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
MinuteCE®Guideline Considerations for Immunotherapy in Primary Advanced or Recurrent Endometrial Cancer
Susana Campos, MD, MPH
Ritu Salani, MD
Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
MinuteCE®Clinical evidence driving guideline recommendations for frontline immunotherapy-based combination regimens in metastatic urothelial cancer
Ignacio Duran, MD
Wenxin Xu, MD
Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
MinuteCE®Guideline-recommended second-line treatment following an immune checkpoint inhibitor in renal cell carcinoma
Ignacio Duran, MD
Wenxin Xu, MD
Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
MinuteCE®Emerging and Practice-Changing Directions in Gynecologic Malignances Involving Combination Therapies With Immune Checkpoint Inhibitors
Susana Campos, MD, MPH
- advertisement
Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
MinuteCE®Insights From Global Key Opinion Leaders on Optimizing Patient Care in Gynecologic Malignances
Susana Campos, MD, MPH
Nicoletta Colombo, MD
Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
MinuteCE®Guideline-recommended first-line treatment with immunotherapy and targeted therapy combinations in renal cell carcinoma
Wenxin Xu, MD
Sandy Srinivas, MD
Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
MinuteCE®Insights from global key opinion leaders on optimizing patient care in genitourinary malignancies
Ignacio Duran, MD
Wenxin Xu, MD
Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
MinuteCE®Guideline-Based, Biomarker-Directed Treatment Options in Second-Line Recurrent Endometrial Cancer
Nicoletta Colombo, MD
Susana Campos, MD, MPH
Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
MinuteCE®Expert Peer Discussion: Integrating Novel HER3-Directed ADCs Upon Disease Progression Following EGFR TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
MinuteCE®Case Application: Adverse Event Management of Patients With EGFRm Resistance Treated With Novel HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
- advertisement
Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
MinuteCE®Case Application: Patients With EGFRm Resistance Post TKI and Platinum Chemotherapy
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
Helena Yu, MD
Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
MinuteCE®Interprofessional Monitoring and Management of AEs With HER3-Directed ADCs
Helena Yu, MD
Pasi Antero Jänne, MD, PhD
